Marker filed its Q2 2026 10-Q today. Three things matter, and only one of them is good.
The good: a new $4.2 million grant from the U.S. Department of War (formerly DoD) to fund MT-601 in relapsed/refractory large B-cell lymphoma, received in July 2026. That’s non-dilutive money aimed directly at the lead program — the third federal agency to underwrite this platform.
The concerning: research and development expense fell 65% year-over-year to $1.5 million for the quarter ($4.3M for the half, down 41%). Payments to Baylor College of Medicine — the entity that actually manufactures MT-601 — dropped from $1.9M in Q2 2025 to $0.5M in Q2 2026. A clinical-stage company that spends less on clinical work is not becoming efficient. It is doing less clinical work.
The absent: it is August 14. The APOLLO dose-expansion readout in DLBCL was guided for 1H 2026. It has not arrived. The most recent clinical data in this filing is still the August 2025 press release with a June 2025 cutoff — 24 B-cell lymphoma patients across 7 sites. Fourteen months of silence on the crown jewel.
Stock closed at $1.14, down 19.7% since the May 15 close of $1.42.
DoW Grant: $4.2M, July 2026, MT-601 in r/r LBCL. Why it matters: This is the single most legitimizing item in the filing. Marker’s non-dilutive stack now runs across CPRIT ($13.1M AML + $9.5M pancreatic), NIH SBIR (four separate awards), the FDA Orphan Products program, and now the Department of War. Federal grant committees do scientific peer review; five agencies independently concluding the MAR-T approach is worth funding is a real external validation of the biology I rated HIGH conviction in the deep dive. It does not, however, validate the stock.
R&D expense: $1.5M in Q2 2026 vs. $4.2M in Q2 2025 (-65%). The company attributes the drop to $2.3M less in clinical trial expenses, $0.3M less in clinical consulting, $0.1M less in other clinical costs. The implication: this is where the catalyst went. You cannot enroll and dose a dose-expansion cohort of an autologous cell therapy while cutting clinical trial spend by two-thirds.
BCM related-party spend: $0.5M in Q2 vs. $1.9M a year ago. BCM currently supplies all MAR-T product. Why it matters: In May I flagged the BCM payable as a yellow flag worth tracking. It’s now $0.8M (down from $1.0M at Q1) and Marker paid nil to BCM during Q2 against $0.5M incurred. But the more revealing number is the expense line, not the payable. Manufacturing spend at your only manufacturer collapsing by 74% means fewer batches are being made.
Cash: $11.9M at June 30, 2026, down from $17.0M at year-end. Six-month operating cash use of $5.1M. Runway now guided “into the second quarter of 2027” — a further extension from the Q1 2027 guidance in May.
ATM: still zero activity. Share count unchanged at 16,673,127 as of August 7. The 130 million authorized shares approved May 1 remain entirely unissued. The 1-for-5 to 1-for-30 reverse split authorized in the March DEF 14A is still unexecuted.
Going concern warning reaffirmed. Unchanged language.
New: IRS penalties of ~$0.5M for failure to timely file Form 5500 filings on the 401(k) plan across plan years 2020–2024. No liability recorded; management is pursuing abatement. The implication: small in dollars, but a five-year lapse in a routine ERISA filing at a company this size is a housekeeping smell, not a rounding error.
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.